Vitexin / IL33 Cancer Research Results

VT, Vitexin: Click to Expand ⟱
Features:

Vitexin - Apigenin-8-C-Glucoside

Alternative Names: Apigenin-8-C-glucoside, apigenin-8-C-β-D-glucopyranoside

Type: Flavone C-glycoside / apigenin derivative

Function: Vitexin is a naturally occurring C-glycosylated flavone in which glucose is attached to apigenin at the C-8 position. It exhibits antioxidant, anti-inflammatory, metabolic, cardiovascular, neuroprotective, and antiproliferative activities and can modulate pathways involving NF-κB, Nrf2/HO-1, MAPK, PI3K/AKT, AMPK, HIF-1α, apoptosis, and oxidative stress.

-see also IsoVitexin

Cancer: Preclinical studies indicate antiproliferative, pro-apoptotic, anti-migratory, anti-invasive, and anti-inflammatory effects across multiple cancer models. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, HIF-1α, ROS, apoptosis, and cell-cycle signaling. Clinical anticancer efficacy has not been established.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective activity through antioxidant and anti-inflammatory effects, reduction of neuronal injury, regulation of oxidative stress and mitochondrial function, and modulation of signaling pathways relevant to cognitive impairment and amyloid-associated neurotoxicity. Clinical efficacy for Alzheimer's disease has not been established.
IL33, Interleukin-33: Click to Expand ⟱
Source:
Type:
IL-33 (Interleukin-33) is a cytokine that plays a crucial role in the regulation of immune responses.
IL-33 has both pro-tumor and anti-tumor effects, depending on the type of cancer and the specific microenvironment.
IL-33 is expressed in various cancers, including breast cancer, colorectal cancer, lung cancer, and gastric cancer. Its expression can vary significantly depending on the tumor type and the immune context.
Elevated levels of IL-33 are often associated with the presence of tumor-infiltrating immune cells and can be produced by both immune and tumor cells.

IL-33 is often considered a pro-tumorigenic cytokine. It can promote tumor growth and survival by enhancing the proliferation and survival of cancer cells. IL-33 can activate signaling pathways such as the NF-κB and MAPK pathways, which are associated with cell proliferation and survival.
Scientific Papers found: Click to Expand⟱
7913- VT,    Review of the effects of vitexin in oxidative stress-related diseases
*antiOx↑, *ROS↓, *lipid-P↓, *memory↑, *Stroke↓, *cardioP↑, *neuroP↑, *Inflam↓, *NRF2↑, *HO-1↑, *NQO1↑, *GRP78/BiP↑, *CHOP/DDIT3↓, *BACE/β-secretase↓, *ChE↓, *AChE↓, *BChE↓, *GSH↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL33↓, *LDH↓, *MDA↓, *SOD↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDH↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   GRP78/BiP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL33↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BChE↓, 1,   ChE↓, 1,  

Protein Aggregation(tgid=19) ⓘ

BACE/β-secretase↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   memory↑, 1,   neuroP↑, 1,  
Total Targets: 27

Scientific Paper Hit Count for: IL33, Interleukin-33
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:462  Target#:630  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page